Full PREVAIL data to be presented at GU Oncology Symposium

On October 22, Medivation and Astellas Pharma had previously announced a positive result to the PREVAIL trial of enzalutamide vs. placebo in the treatment of men with chemotherapy-naive, metastatic castration-resistant prostate cancer.

In another media release, issued late last week, the companies have now announced, as we had originally hoped, that the full results of this trial will be presented at the upcoming Genitourinary Cancers Symposium in San Francisco at the end of January.

According to the media release, this will be an oral presentation to be given early on the morning of January 30 by Tomasz M. Beer, MD, of the OHSU Knight Cancer Institute, Oregon Health & Science University.

4 Responses

  1. Sitemaster:

    As you report, in the PREVAIL Trial, the median survival for patients taking enzalutamide was about 32 months, and the median survival for patients taking a placebo was about 30 months. In my mind, that would equate to about a 7 percent survival benefit, in terms of length of survival (a very modest benefit). However, the correct statistical reading of the results, apparently, is a 30% decrease in risk of death (a much more significant result). Can you please assist this statistically-naive reader with a point in the right direction to a publication which explains prostate cancer trial statistical results? Thank you.

    Richard Stanton

  2. I hope to see you there, Mike. It will be a very interesting ASCO GU summit. The CHAARTED data is supposed to be released there as well.

  3. Another good reason, CHAARTED the other, to be there. I hope to see you there, Mike…

  4. Dear Richard:

    Alas, your sitemaster does not claim to have the statistical knowledge or sophistication to be able to either explain these types of distinction or be able to provide you with a relevant reference. What he does know is that “correct” statistical readings may be in the eye of the interpreter!

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: